Key Takeaways:
- Eli Lilly is still one of the market’s most important obesity and diabetes stories, and recent price action reflects both strong product momentum and a high valuation bar.
- LLY stock could reasonably reach $1,373 per share by 12/31/28, based on the valuation model provided in the attached materials.
- This implies a 44.1% total return from today’s price of $953, with a 14.3% annualized return over the next 2.7 years.
What Happened?
Eli Lilly and Company (LLY) is back in focus because the company just turned one of its biggest pipeline opportunities into a commercial launch. On April 1, the FDA approved Foundayo, Lilly’s oral GLP-1 pill for chronic weight management, and Lilly said the drug can be taken any time of day without food or water restrictions.
The stock is also reacting to the commercial implications of that approval. Reuters reported that Lilly shares jumped nearly 6% after the FDA decision, while Wall Street began framing Foundayo as a potential multi-billion-dollar product despite competition from Novo Nordisk. Investors are now debating how much of Lilly’s next obesity leg is already reflected in the stock.
There is more going on than one approval. On April 9, Reuters reported Amazon Pharmacy will stock Foundayo at select kiosks and offer same-day delivery in some markets, which supports Lilly’s push to widen access through distribution and convenience. But Reuters also reported Lilly expects a roughly $584 million acquired IPR&D charge in Q1, equal to about $0.52 per share, so the market is balancing launch momentum against ongoing deal and pipeline costs.
The next major catalyst is earnings. Lilly’s investor relations site lists its Q1 2026 earnings call for April 30, and its 2026 proxy materials point to the annual shareholder meeting on May 4. Investors will likely watch early Foundayo uptake, Mounjaro and Zepbound demand, pricing, and manufacturing progress because those factors help explain why the stock trades at a premium multiple today.
Here’s why Eli Lilly stock could stay active from here: the company has real commercial momentum, but the market is now asking whether new obesity products, pipeline wins, and manufacturing scale can justify a valuation that already assumes years of strong execution.
What the Model Says for LLY Stock
We analyzed the upside potential for Eli Lilly stock using valuation assumptions tied to its obesity franchise, operating leverage, and earnings power. The business has grown much faster over the last two years, and that has pushed both profits and expectations higher.
Based on estimates of 18% annual revenue growth, 41.8% operating margins, and a normalized P/E multiple of 27.5x, the model projects Eli Lilly stock could rise from $953 to $1,373 per share.
That would be a 44.1% total return, or a 14.3% annualized return over the next 2.7 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for LLY stock:
1. Revenue Growth: 18%
Lilly’s revenue growth has been extraordinary, and the biggest driver has been cardiometabolic demand. In Q4 2025, revenue rose 43% to $19.3 billion, led by Mounjaro and Zepbound, while full-year revenue reached $65.2 billion. Mounjaro generated $23.0 billion in 2025 revenue, and Zepbound generated $13.5 billion, which shows how central those products are to the current investment case.
The growth story also now includes an oral format. Foundayo gives Lilly a pill-based obesity option, and Reuters reported that many patients and physicians see pills as more convenient and potentially more accessible than injections. That does not guarantee the same economics as injectables, but it does broaden the commercial opportunity and helps explain why the stock remains sensitive to obesity-related headlines.
Lilly’s pipeline is also still adding support to the top-line story. On March 19, Lilly said retatrutide lowered A1C by 1.7% to 2.0% and delivered up to 16.8% weight loss in the first Phase 3 diabetes study, which reinforces the depth of its cardiometabolic pipeline.
Based on analysts’ consensus estimates, we use 18% revenue growth. That is below Lilly’s 44.7% growth in 2025, so it reflects natural slowing from a much larger base, but it still assumes obesity, diabetes, and pipeline launches remain powerful growth drivers.
2. Operating Margins: 41.8%
Lilly’s recent margin profile is one reason the stock has stayed expensive. The company’s 2025 gross margin reached 83.0%, and its operating margin reached 45.6%, based on the financial figures you supplied. Those numbers show Lilly is not just growing quickly; it is also doing so with unusually strong profitability.
Recent company commentary helps explain why margins have remained so strong. Lilly said Q4 2025 gross margin improved on a favorable product mix and improved cost of production, even as lower realized prices created some offset. In plain terms, Lilly is selling more of its highest-value products, and manufacturing economics are improving as scale increases.
There are still real costs underneath that growth. Q4 2025 R&D expense increased 26% to $3.8 billion, and marketing, selling, and administrative expense rose 29% to $3.1 billion as Lilly supported current and planned launches. That means profitability is strong today, but Lilly is also spending heavily to defend its lead and expand future capacity.
Based on analysts’ consensus estimates, we use 41.8% operating margins. That sits below the latest trailing level, so it builds in some normalization as Lilly continues to invest in launches, R&D, and manufacturing.
3. Exit P/E Multiple: 27.5x
The multiple is where the debate gets harder. Based on the overview figures you supplied, Lilly trades at about 27.5x NTM earnings, 21.8x NTM EBITDA, and 10.9x NTM revenue, while LTM P/E is about 41.5x. Those are premium levels, and they tell you the market is already paying up for durability, growth, and product leadership.
That premium is supported by the current business trajectory. Lilly’s street target price was about $1,209 as of April 8, 2026, with 29 analysts covering the name, and the mean target stood at roughly 126.8% of the then-current price in your supplied valuation table. At the same time, Reuters reported analysts see multi-billion-dollar sales potential for Foundayo, which helps explain why the market has not sharply derated the stock despite tougher competition.
Management’s own guidance also supports a premium setup. In February, Lilly guided 2026 revenue to $80 billion to $83 billion and non-GAAP EPS to $33 to $35, while CEO David Ricks said Lilly had “expanded our manufacturing capacity” and was positioned to reach more patients than ever. That does not prove the multiple is cheap, but it does show why investors continue to assign Lilly a leadership premium.
Based on analysts’ consensus estimates, we maintain a 27.5x exit P/E multiple. That matches the valuation model you provided and already assumes some moderation relative to Lilly’s trailing earnings multiple. For shareholders, that means most of the return case rests on earnings growth staying strong, not on the market paying an even richer multiple later.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for LLY stock through 2030 show varied outcomes based on obesity demand, margin execution, and valuation discipline (these are estimates, not guaranteed returns):
- Low Case: obesity growth slows, pricing pressure increases, and valuation compresses faster → 8.4% annual returns
- Mid Case: Lilly keeps scaling Mounjaro, Zepbound, and Foundayo while margins stay strong → 11.9% annual returns
- High Case: Pipeline execution stays strong, obesity access expands, and the valuation remains resilient → 15.1% annual returns
Going forward, Lilly stock will likely move on launch data, reimbursement progress, manufacturing updates, and new clinical results more than on broad market noise. The April 30 earnings call matters because investors want proof that Foundayo can add to growth without damaging Lilly’s profit story.
If Lilly keeps delivering high growth and high margins, the valuation can stay elevated, but the stock’s next move will still depend on execution staying very strong.
See what analysts think about LLY stock right now (Free with TIKR) >>>
Should You Invest in Eli Lilly and Company?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up LLY, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track LLY alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
